Otenabant
From Self-sufficiency
Revision as of 16:23, 28 February 2010 by حسن علي البط (Talk) (Quick-adding category Organochlorides (using HotCat))
| File:Otenabant.svg | |
| Systematic (IUPAC) name | |
|---|---|
|
1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(ethylamino)piperidine-4- carboxamide | |
| Identifiers | |
| CAS Number | 686344-29-6 |
| ATC code | none |
| Chemical data | |
| Formula | C25H25Cl2N7O |
| Molar mass | 510.4[[Script error: No such module "String".]] |
Otenabant (CP-945,598) is a drug which acts as a potent and highly selective CB1 antagonist.[1] It was developed by Pfizer for the treatment of obesity,[2] but development for this application has been discontinued following the problems seen during clinical use of the similar drug rimonabant.[3]
See also
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 40px | This article about a cannabinoid is a stub. You can help ssf by expanding it. |
- ↑ Kim, M.; Yun, H.; Kwak, H.; Kim, J.; Lee, J. (2008), "Design, chemical synthesis, and biological evaluation of novel triazolyl analogues of taranabant (MK-0364), a cannabinoid-1 receptor inverse agonist" (PDF), Tetrahedron, 64: 10802 – 10809, doi:10.1016/j.tet.2008.09.057
- ↑ Woods SC. The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction. Journal of the American Academy of Physician Assistants. 2007 Nov;Suppl Endocannabinoid:7-10. PMID 18047036
- ↑ http://www.pfizer.com
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Cannabinoids
- Purines
- Piperidines
- Amides
- Organochlorides
- Cannabinoid stubs
- 2Fix
